Raising $13.4 million in seed investment, Radar Therapeutics is a biotech business situated in Berkeley, CA that develops smart programmable medications.
Investors
- NfX Bio
- PearVC
- BEVC
- Eli Lilly and Company
- Biovision Ventures
- KdT Ventures
Use of funds
The business plans to utilize the money for staff growth, partnerships, and internal program development.
Scientific advisory board Members
- Xiaojing Gao, Ph.D., Co-Founder
- James J. Collins, Ph.D., Co-Founder
- David Schaffer, PhD
- Eric Klein, M.D.
- Svetlana Lucas, PhD comprise
About Radar
Radar is creating programmable genetic and mRNA-based therapeutics under the direction of Sophia Lugo, CEO, and Eerik Kaseniit, PhD, CSO, and President. RNA sensors, or mRNAs that gate their expression based on other RNAs in the cell, are used to express specific payloads, allowing for the targeted and timed delivery of the drug payload into the appropriate cells at the appropriate time. Precision medicines may be made “smart,” or logically designed, thanks to the RADAR platform.
